HealthcareMid capRs 13,885 crRs 21.4 cr traded a day
Close on 10 September 2026
577.35
−1.53%
52-week range82% of the way up
423.50611.65
Market cap
13,885 cr
P/E (TTM)
34.6×
industry 45×
EPS (TTM)
16.67
Revenue YoY
+39.7%
Q1 FY27
Profit YoY
-0.2%
Net margin
10.9%
-4.4pt vs a year ago
Growth trend
+6.9pt
vs last quarter’s YoY
1 month
+2.1%
Below 52w high
5.9%
RSI (14)
55
Daily swing
2.8%
average true range
Volume
0.4×
vs 20-day average
Traded
Rs 21 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Above the median
+13.3%
One-year return
Around the median
-0.0%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+39.7%
Below the 52-week high
from the highest close of the year
-5.6%
1 week
−3.80%
1 month
+2.11%
3 months
+12.41%
6 months
+27.51%
1 year
−0.04%
The read
written from the numbers on this page
The evidence leans constructive6 supporting, 2 against, 0 worth knowing
Supporting
trading 13% above its 200-day average
matches the market's strongest stocks, which has beaten the market by +0.59 points over 20 sessions across 51,498 past signals
3 of the scans it matches have a positive measured record
3 independent kinds of evidence agree today, which is uncommon
revenue grew 40% year on year in the quarter ending 30 June 2026
priced at 35× earnings against an industry median of 45× — 23% below its peers
Against
down 0% over twelve months
net margin has narrowed from 12.7% to 10.9% across four quarters
Worth knowing
nothing the data supports either way
What would change this read: a close below 510, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working3
Revenue rose 39.7% year on year, from Rs 761 cr to Rs 1,063 cr.
+39.7%Rs 761 crRs 1,063 cr
Trading 13.3% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+13.3%
Turned up over three months while the year is still negative.
+12.4% 3M-0.0% 1Y
Needs watching3
Profit growth was -0.2%, while revenue growth was +39.7%, showing a significant gap.
-0.2%+39.7%
Net margin fell from 15.3% to 10.9% this quarter versus last year.
15.3%10.9%
Enterprise Commercial Solutions accounts for 71% of revenue, making it the largest reported segment.
Enterprise Commercial Solutions71%
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 4 of these 4 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
4 of 47 matched on 10 Sep
INDGN matches 4 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
segments and revenue mix, as the company reports them
INDGN reports 3 business segments. The largest is Enterprise Commercial Solutions at 71% of revenue in the quarter ending 30 June 2026.
SegmentRevenueSharevs a year ago
Enterprise Commercial Solutions750 cr70.6%—
Enterprise Medical Solutions274 cr25.7%—
Others39 cr3.7%—
Segment names are the company’s own, taken verbatim from the reportable-segment disclosure in its quarterly XBRL filing. Nothing on this page describes the business in words we wrote.
Valuation against its own history
411 sessions since 30 January 2025
25×
median 31×
36×
now 35×
INDGN trades at 35× trailing earnings, above its median of 31× over this window — 11% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Legal / regulatory filings were typically +0.62pt vs the market over the next 5 sessions (n=137) · Analyst call filings were typically +0.11pt vs the market over the next 5 sessions (n=4,339) · Management filings were typically +0.06pt vs the market over the next 5 sessions (n=2,634)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 40% against the same quarter a year earlier
net margin widened from 7.9% to 10.9%
revenue rose in 4 of the last 4 quarters
Going against it
profit dropped 0% year on year
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
1,063
153
116
4.84
10.9%
Q4 FY26
31 Mar · consolidated
1,003
105
80
3.32
7.9%
Q3 FY26
31 Dec · consolidated
942
135
103
4.29
10.9%
Q2 FY26
30 Sep · consolidated
804
133
102
4.26
12.7%
Q1 FY26
30 Jun · consolidated
761
152
116
4.86
15.3%
Q4 FY25
31 Mar · consolidated
756
149
118
4.91
15.6%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+6.0%
Versus 200-day average+13.3%
Below 52-week high-5.6%
Above 52-week low+36.3%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)55.1
Higher closes in last 51 of 5
Six-month return+27.51%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.84%
Volume versus 20-day0.4x
Median daily turnoverRs 21.4 cr
Peers
Healthcare · 68 classified companies
INDGN trades at 34.6× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — cheaper than them, by 23%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
31 Aug
2
MACD just turned positive, Growing fast and near a high